









Markets
/
Stocks
/
nasdaq-anik
/

Anika Therapeutics Inc

ANIK

9.750USD

-0.100-1.02%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

140.58MMarket Cap

LossP/E TTM



Anika Therapeutics Inc

9.750

-0.100-1.02%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Anika Therapeutics Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Anika Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

31 / 210

Overall Ranking

97 / 4615

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

16.000

Target Price

+62.44%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Anika Therapeutics Inc Highlights

StrengthsRisks

Anika Therapeutics, Inc. is a global joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care, including in the areas of osteoarthritis (OA) pain management, regenerative solutions, and sports medicine. It is focused on developing, manufacturing and commercializing products on its hyaluronic acid (HA), technology platform. Its OA Pain Management product family consists of Monovisc and Orthovisc, its injectable, HA, OA Pain Management offerings are indicated to provide pain relief from osteoarthritis conditions; and Cingal, its novel, next generation, single-injection OA Pain Management product consisting of its proprietary cross-linked HA material combined with a steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products utilizing HA, including Integrity, its new hyaluronic acid-based scaffold for rotator cuff and other tendon repairs.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 119.91M.

Overvalued

The company’s latest PE is -2.36, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 13.09M shares, decreasing 8.19% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 1.16K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 8.27, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 28.22M, representing a year-over-year decrease of 32.69%, while its net profit experienced a year-over-year decrease of 4411.36%.

Score

Industry at a Glance

Previous score

8.27

Change



Financials

8.72

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.72

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.49

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.41

Key Metrics

Free cash flow

No Data

Anika Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 8.80, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -2.36, which is -16.92% below the recent high of -1.96 and -1234.30% above the recent low of -31.46.

Score

Industry at a Glance

Previous score

8.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 31/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 9.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Anika Therapeutics Inc is 16.00, with a high of 16.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

16.000

Target Price

+62.44%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

110

Total

Median

Average

Company name

Ratings

Analysts

Anika Therapeutics Inc

ANIK

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 6.56, which is lower than the Healthcare Equipment & Supplies industry's average of 6.74. Sideways: Currently, the stock price is trading between the resistance level at 10.78 and the support level at 8.70, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.63

Change

-0.07

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.001

Buy

RSI(14)

55.843

Neutral

STOCH(KDJ)(9,3,3)

31.647

Sell

ATR(14)

0.421

Low Volatility

CCI(14)

-42.152

Neutral

Williams %R

64.935

Sell

TRIX(12,20)

0.308

Sell

StochRSI(14)

35.338

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

9.760

Sell

MA10

9.771

Sell

MA20

9.549

Buy

MA50

9.230

Buy

MA100

9.648

Buy

MA200

12.195

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-06

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.40. The latest institutional shareholding proportion is 90.76%, representing a quarter-over-quarter decrease of 4.78%. The largest institutional shareholder is The Vanguard, holding a total of 779.47K shares, representing 5.41% of shares outstanding, with 3.46% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Trigran Investments, Inc.

2.04M

-0.26%

Caligan Partners, LP

1.44M

BlackRock Institutional Trust Company, N.A.

937.30K

-2.10%

The Vanguard Group, Inc.

Star Investors

779.47K

+0.27%

Dimensional Fund Advisors, L.P.

623.08K

+1.48%

Opaleye Management Inc.

588.80K

+49.06%

Acadian Asset Management LLC

575.64K

+6.68%

The Capital Management Corporation

408.85K

+24.02%

BlackRock Financial Management, Inc.

546.12K

+4.62%

Boothbay Fund Management, LLC

529.50K

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 3.29, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.50. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.